Congress highlights: Melanoma

For conference highlights from Chicago, MEDtalks is the place to be. 

In this on-demand video, dr. John Haanen, medical oncologist at the Antoni van Leeuwenhoek Hospital in Amsterdam, shares his personal highlights for early-stage and metastatic melanoma. Of course, he takes into account the Dutch practice. 

By watching this video you are immediately up to date with the latest news on melanoma, without having to leave your practice.

Dr. Haanen discusses the following topics: 

Early-stage melanoma 

• Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
• Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
• Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Metastatic melanoma

• Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)
• Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048
• Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A